en · de · es · pt
tb-500-notes.peptides6088.com › Topic › Identification And Molecular Background — Complete Guide

Identification And Molecular Background — Complete Guide

By Editorial Desk · published 2026-03-13 · last reviewed 2026-04-19 · Topic

actin-binding motif raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-04-19 and is reviewed periodically as new material appears.

Identification and Molecular Background

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

Storage and Analytical Verification

Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.

Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.

Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.

Tb-500 at a glance

PropertyValueNotes
Generic designationSynthetic thymosin beta-4 N-terminal fragmentPeptide nomenclature varies by supplier
Peptide lengthApproximately 17 amino acid residuesReported length sometimes differs between sources
N-terminal modificationAcetyl groupAffects mass and chromatographic behaviour
Compound classSmall synthetic peptideNot a small-molecule drug
Common synonymsTB4 fragment; thymosin beta-4 fragmentNaming is inconsistent in popular media

TB-500 Identity and Naming Background

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

Related pages on this site

Identity And Naming Background

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

Notes from published material

Can be used for purification on Protein-A Sepharose Designed Intrinsically Disordered tags containing disorder promoting amino acids (P,E,S,T,A,Q,G,..) Carbohydrate Recognition Domain or CRDSAT-tag, a protein which binds to lactose agarose or Sepharose

A protein called divalent metal transporter 1 (DMT1), which can transport several divalent metals across the plasma membrane, then transports iron across the enterocyte's cell membrane into the cell. If the iron is bound to heme it is instead transported across the apical membrane by heme carrier protein 1 (HCP1). These intestinal lining cells can then either store the iron as ferritin, which is accomplished by Fe2+ binding to apoferritin (in which case the iron will leave the body when the cell dies and is sloughed off into feces), or the cell can release it into the body via the only known iron exporter in mammals, ferroportin. Hephaestin, a ferroxidase that can oxidize Fe2+ to Fe3+ and is found mainly in the small intestine, helps ferroportin transfer iron across the basolateral end of the intestine cells. In contrast, ferroportin is post-translationally repressed by hepcidin, a 25-amino acid peptide hormone. The body regulates iron levels by regulating each of these steps. For instance, enterocytes synthesize more Dcytb, DMT1 and ferroportin in response to iron deficiency anemia. Iron absorption from diet is enhanced in the presence of vitamin C and diminished by excess calcium, zinc, or manganese. The human body's rate of iron absorption appears to respond to a variety of interdependent factors, including total iron stores, the extent to which the bone marrow is producing new red blood cells, the concentration of hemoglobin in the blood, and the oxygen content of the blood.

=== EC 1.7.3 With oxygen as acceptor === EC 1.7.3.1: nitroalkane oxidase EC 1.7.3.2: acetylindoxyl oxidase EC 1.7.3.3: factor-independent urate hydroxylase EC 1.7.3.4: Now covered by EC 1.7.2.6, hydroxylamine dehydrogenase, and EC 1.7.3.6, hydroxylamine oxidase (cytochrome) EC 1.7.3.5: 3-aci-nitropropanoate oxidase EC 1.7.3.6: hydroxylamine oxidase (cytochrome)

=== Location and Position === The apical foramen is the principal opening at a tooth's root terminus, serving as the conduit between the root canal system and the periapical tissues. Its location is variable, as it frequently deviates from the anatomical apex—the root's geometric tip. Studies indicate that in a majority of cases, the foramen is positioned laterally, most commonly on the distal aspect. The average deviation is typically less than 1 millimeter, though greater distances are observed in specific teeth such as mandibular canines and molars. The foramen's morphology is often oval but can be circular or irregular. Its precise location and shape can be influenced by ethnic background, age, and physiological changes. In clinical endodontics, accurate identification of the apical foramen, rather than reliance on the radiographic apex alone, is essential for determining the correct working length and ensuring treatment success.

Sources: en.wikipedia.org

Background from the literature

In situ leaching or in situ recovery refers to the mining technique of injecting lixiviant underground to dissolve ore and bringing the pregnant leach solution to surface for extraction. Commonly used in uranium mining but has also been used for copper mining.

Chromatography columns Gravity-flow columns Chromatography cartridges Centrifuge columns Centrifuge plates Gravity-flow, or drip, columns use head-pressure from a buffer-chase to push the sample through the gel filtration matrix. Sample is loaded into the top of an upright column and allowed to flow into the resin bed. The sample is then chased through the column by adding additional buffer or water to the top of the column. During this process, small fractions are typically collected and each is tested for the macromolecules of interest. In some cases, several fractions might contain the protein and may have to be pooled to improve yield. In order to eliminate the time and monitoring assorted with drip columns, fractions often equal to the full exclusion volume of the column are collected regardless of sample volume resulting in significant dilution of sample. Sealed chromatography cartridges or columns work similarly except the sample and buffer is pumped into and through the resin by an external device such as a liquid chromatographic (LC) system, also requiring collection and monitoring of several fractions. Even though this method is often semi-automated, using chromatography cartridges is typically limited to processing one sample at a time and some sample dilution from the chase buffer is still likely to occur. To eliminate sample dilution and the collecting and monitoring of fractions, centrifuge column or plate -based gel filtration, also referred to as spin desalting, methods are commonly used.

Traditional additive solutions are hypotonic, although experiments with next-generation additive solutions suggest that an alkali pH in combination with low chloride concentrations may be able to prolong the red blood cell viability. Leucocyte depletion of blood components, including red blood cell concentrates, is increasingly becoming standard practise; in many of the high-income countries of the world, 100% of the red blood cell supply is already being leucocyte depleted. Leucocyte depletion, usually by a leucocyte filter included in the blood bag system, is an efficient yet relatively cheap way of reducing the risk of transfusion reactions. Leucocyte depletion is most commonly performed as an integrated processing step, as bedside filtration is considered a less efficient method.

Sources: en.wikipedia.org

Further detail

=== Activity profile === Flibanserin acts as a full agonist in the frontal cortex and the dorsal raphe nucleus, but only as a partial agonist in the CA3 region of the hippocampus of the 5-HT1A receptor (serotonin receptor) (Ki = 1 nM in CHO cells, but only 15–50 nM in cortex, hippocampus and dorsal raphe) and, with lower affinity, as an antagonist of the 5-HT2A receptor (Ki = 49 nM) and antagonist or very weak partial agonist of the D4 receptor (Ki = 4–24 nM, Ki = 8–650 nM). Flibanserin demonstrates selectivity for postsynaptic 5-HT1A receptors. Despite the much greater affinity of flibanserin for the 5-HT1A receptor, and for reasons that are unknown (although it might be caused by the competition with endogenous serotonin), flibanserin occupies the 5-HT1A and 5-HT2A receptors in vivo with similar percentages. Flibanserin also has low affinity for the 5-HT2B receptor (Ki = 89.3 nM) and the 5-HT2C receptor (Ki = 88.3 nM), both of which it behaves as an antagonist of. Flibanserin preferentially activates 5-HT1A receptors in the prefrontal cortex, demonstrating regional selectivity, and has been found to increase dopamine and norepinephrine levels and decrease serotonin levels in the rat prefrontal cortex, actions that were determined to be mediated by activation of the 5-HT1A receptor. As such, flibanserin has been described as a norepinephrine–dopamine disinhibitor (NDDI). The proposed mechanism of action refers to the Kinsey dual control model of sexual response.

The tavern serves steak, lamb, venison, duck, and rabbit. In 1956, Cold Spring Tavern was the first restaurant to serve Steve Henson's original salad dressing. Henson and his wife had recently moved to a nearby guest ranch they renamed “Hidden Valley Ranch”, and decided to try marketing the dressing in the area when it became popular with guests. Audrey Ovington, a friend of the Hensons who owned the tavern at the time, was their first commercial customer, and the condiment has since been known as ranch dressing.

Solanine is a glycoalkaloid poison created by various plants in the genus Solanum, such as the potato plant. When the plant's stem, tubers, or leaves are exposed to sunlight, it stimulates the biosynthesis of solanine and other glycoalkaloids as a defense mechanism so it is not eaten. It is therefore considered to be a natural pesticide. Though the structures of the intermediates in this biosynthetic pathway are shown, many of the specific enzymes involved in these chemical processes are not known. However, it is known that in the biosynthesis of solanine, cholesterol is first converted into the steroidal alkaloid solanidine. This is accomplished through a series of hydroxylation, transamination, oxidation, cyclization, dehydration, and reduction reactions. Specifically, solanidine formation involves sequential hydroxylation, transamination, and cyclization reactions.The solanidine is then converted into solanine through a series of glycosylation reactions catalyzed by specific glycosyltransferases. Plants like the potato and tomato constantly synthesize low levels of glycoalkaloids like solanine. However, under stress, such as the presence of a pest or herbivore, they increase the synthesis of compounds like solanine as a natural chemical defense. This rapid increase in glycoalkaloid concentration gives the potatoes a bitter taste, and stressful stimuli like light also stimulate photosynthesis and the accumulation of chlorophyll. As a result, the potatoes turn green, and are thus unattractive to pests.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 chemically?

It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.

Where does the name come from?

The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.

How is the powder stored before use?

Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.

Network